<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Physiology Development and Neuroscience</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9C061171-8907-49E7-AC38-0921B879C200"><gtr:id>9C061171-8907-49E7-AC38-0921B879C200</gtr:id><gtr:firstName>Shiraz</gtr:firstName><gtr:surname>Ahmad</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM001288%2F1"><gtr:id>FD35F108-381C-4E3B-9E71-CD78DFE567AB</gtr:id><gtr:title>Cardiac arrhythmogenesis in the PGC-1alpha -/- murine system</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/M001288/1</gtr:grantReference><gtr:abstractText>Sudden cardiac death is a major cause of death worldwide. The total number of deaths attributable to sudden cardiac death is second only to all cancer types combined. It most frequently occurs with electrical disorders in the heart that result from its deprivation of oxygen following a heart attack. It has been suggested that the likelihood of this fatal outcome is worsened by the presence of certain cardiac conditions affecting its electrical behaviour, particularly under conditions of abnormal energy utilization by the heart muscle itself. 

There is accumulating evidence for abnormal energy utilization in two important human diseases: diabetes mellitus and heart failure. The latter conditions, as well as their associated complications of cardiac electrical conditions, are currently important public health problems, and will increase in importance in the future. Large studies of human patients point towards diabetes mellitus being an independent risk factor for sudden cardiac death, supporting a hypothesis that the disruption of energy pathways in human heart cells is a final common pathway to electrical abnormalities in these two diseases. 

I will use a genetically modified mouse model for both these conditions to test such a hypothesis. This will involve studying the electrical activity of the heart at the whole organ, single heart chamber and cellular level to test such a hypothesis and ascertain the reasons for such findings. Recordings of the electrical activity of the genetically modified mouse heart will be made in the presence and absence of drugs known to provoke electrical disorders of the heart. From these recordings, parameters of electrical properties of the modified mouse heart will be extracted and analysed, to ascertain whether the heart muscle itself is triggering the electrical instability, or whether changes in the heart muscle are rendering it more susceptible to the perpetuation of abnormal electrical currents, or both are true to a greater or lesser extent. This will allow us to isolate potential targets to reverse these abnormalities through the use of established drugs thought to act on both the electrical and the metabolic properties of the heart. 

I will then apply these findings to the specific development of two possible novel drugs with contrasting mechanisms of action that may reduce the cardiac risks of diabetes, heart failure and associated conditions, as well as in normal subjects following heart attacks.</gtr:abstractText><gtr:technicalSummary>Sudden cardiac death is a major cause of death worldwide. The total number of deaths attributable to sudden cardiac death is second only to all cancer types combined. Arrhythmogenesis most frequently results from ischaemic conditions; however accumulating evidence implicates energetic dysfunction, particularly metabolic syndrome, diabetes and obesity as independent risk factors. I will link metabolic abnormality to cardiac arrhythmogenesis in the PGC1alpha-/- murine system. This system contains a gene deletion associated with disrupted mitochondrial bioenergetics, altered calcium homeostasis and cardiac failure in a background of diabetogenic changes. I will establish and quantify electrophysiological instabilities by testing for arrhythmic substrate with electrocardiographic and monophasic action potential recordings at the whole heart level. I will then identify the electrophysiological and cellular basis of the arrhythmic phenotype with a dissection of the causal relationship between arrhythmia triggering and perpetuating events, mechanistic studies of ion channel behaviour using patch clamp electrophysiological techniques and confocal microscopy to assess Ca2+ homeostasis in isolated cells. Having clarified arrhythmic mechanisms in this system, I will translate these findings to the development of two novel therapeutic agents undergoing clinical trials; the sarcoplasmic reticular Ca2+-ATPase (SERCA) activator, istaroxime and the late Na+ current blocker ranolazine. This will extend their use to the management of cardiac arrhythmia in metabolic conditions.</gtr:technicalSummary><gtr:potentialImpactText>Beneficiaries of our research are likely to be widespread and include

1) The scientific community. The research proposed is fundamental to the understanding of arrhythmia and its propagation, a question of particular importance to electrophysiologists, but also of importance to the study of biological pattern generation in neuroscience. Our research will link the underlying metabolic dysregulation to cell membrane and intra-cellular currents, bridging research between molecular disturbances and physiological effects. This will allow this novel paradigm to be scrutinized as a platform for the analysis of electrophysiological abnormalities in a range of cardiac and neurological diseases. Our research will be of relevance to biochemical science researchers and cell biologists, who will gain insight into the role of the PGC-1/PPAR axis in cardiac function, the phenotypic manifestations of PGC-1alpha ablation in cardiac tissue and correlation of such manifestations with electrical and cellular abnormalities.
2) The Medical Community. Resolution of the role of triggering and re-entry in arrhythmia will unify theories of arrhythmia in a wide array of biological systems and diseases. This is the first step in identifying novel therapeutic strategies for electrophysiological conditions such as atrial fibrillation. Our research will be the first study to identify how the independent risk conferred by diabetes and cardiac failure for arrhythmia is mediated at a cellular level in a murine model. This will strengthen our ability to characterise discrete sudden cardiac death (SCD) syndromes such as the &amp;quot;dead in bed&amp;quot; syndrome which is associated with diabetes. It will also open avenues of research for reduction in morbidity and mortality in these populations. Finally, the central hypothesis of energetic dysfunction causing arrhythmia has important implications for clinicians managing patients with conditions such as diabetes and could prompt more in depth population stratification to identify patients at risk and those who would benefit from targeted intervention. This will enable appropriate provision of health resources and heighten and direct vigilance among clinicians to these risks.
3) Health Science Industries. Our proposition for the use of ranolazine and istoraxime will be a proof-of-concept that the arrhythmic phenotype in the PGC-1alpha -/- heart can be rescued by targeted manipulation. This will establish these drugs as potential anti-arrhythmic agents for use in humans. Our elucidation of basic arrhythmic mechanisms opens new possibilities for the rationale behind anti-arrhythmic drug selection and development in the future. 
4) University Students. The project will give the opportunity for Natural Science and Pre-Clinical Medicine students to learn cutting edge electrophysiological research, formulate and analyse key research questions. It will facilitate their development of logical reasoning and effective communication.
5) Health Policy Makers. This research will impact upon research to quantify the future demand of automated electrical defibrillator (AED) provision in the community as the prevalence of diabetes and heart failure increase. It will also likely form a consideration in future workforce planning for the provision of specialist and subspecialist clinicians in cardiology. 
6) UK economic performance. Electrophysiology lies on the cusp of the biological and physical sciences, a relatively underdeveloped area. The necessary acquisition of electrophysiological research skills is possessed by relatively few individuals, yet is likely to become increasingly important as biomedical devices grow in importance. An understanding of biophysics and the direct manipulation of the electromechanical substrate of biological systems by both technological means as well as cellular means is a vital research skill base that must be maintained by the UK in order to remain competitive in future technological advancement.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-09-14</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-09-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>226777</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Department of PDN Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9B1269CB-F28E-4C8A-89E6-4E375B30ADB2</gtr:id><gtr:impact>Open day at the Department of PDN that was attended by all research groups across the department. Allowed critical review of the research questions and techniques used to address these - appraisal of results so far. This sparked discussion on the future research direction and next experimental steps.</gtr:impact><gtr:outcomeId>56d83461bc8e79.40256556</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual Sudden Arrhythmic Death Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0DCC2A8C-5C4D-4D13-947E-B161DB00258A</gtr:id><gtr:impact>Presentation at the national SADS conference. Attended by patients, patient groups, medical and allied health practitioners and scientific researchers. Aimed to disseminate research progress among professionals active in electrophysiological research as well as clinicians. Presentation of research and importance of research for understanding clinical syndromes. Presentation led to discussion among a wide range of interested patient groups as well as scientific researchers pursuing similar avenues</gtr:impact><gtr:outcomeId>56d83542eae987.01326083</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The method provides a way to assess the ionic current characteristics in intact tissue preparations. It relies on the formation of 'loose' patch clamp seals (&amp;lt; 1MOhm). This requires a new method for fabrication of specialized glass pipettes and methods to deconvolve the current signal from the leak current. Its primary advantage over tight patch clamping is its ability to measure current characteristics in intact tissue preparations which are the natural substrate for arrhythmias, allowing for multiple patching of the same area of membrane so that drug effects can be tested</gtr:description><gtr:id>4AE62D61-07AD-4F3C-B5C1-82C5D2CB3168</gtr:id><gtr:impact>We have used this method to enable a comparison between sodium current density in intact ventricular and atrial tissue in the murine RYR-P2328S model of the human condition CPVT. This has led to new insights that the arrhythmic mechanisms of what were previously considered to be purely 'triggered' arrhythmias may in fact have a substantial 'substrate' component due to slowed conduction velocity.</gtr:impact><gtr:outcomeId>56d429f8d366a7.76451467</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Whole Cell Loose Patch Clamp</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3A4DBE5B-D5EB-4C48-9C10-8187C15A673E</gtr:id><gtr:title>Cardiomyocyte ionic currents in intact young and aged murine Pgc-1?atrial preparations.</gtr:title><gtr:parentPublicationTitle>Mechanisms of ageing and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/536c54e6501c9878b51f8195fca5c162"><gtr:id>536c54e6501c9878b51f8195fca5c162</gtr:id><gtr:otherNames>Valli H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0047-6374</gtr:issn><gtr:outcomeId>5a6169f13da026.97496497</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>815CE2AF-124E-4DEA-B368-0B6BBC5C991A</gtr:id><gtr:title>Murine Electrophysiological Models of Cardiac Arrhythmogenesis.</gtr:title><gtr:parentPublicationTitle>Physiological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b89cd909004e1ac07fb1ab74d2c10d3"><gtr:id>6b89cd909004e1ac07fb1ab74d2c10d3</gtr:id><gtr:otherNames>Huang CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-9333</gtr:issn><gtr:outcomeId>5a2fd9a6cd1f22.26151370</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6A6CE05-C5BC-4AC7-95FC-1CA2C3BADE9B</gtr:id><gtr:title>Ion channels, long QT syndrome and arrhythmogenesis in&amp;nbsp;ageing.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental pharmacology &amp; physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb5bbfe414eb00db62454691d5b71093"><gtr:id>bb5bbfe414eb00db62454691d5b71093</gtr:id><gtr:otherNames>Jeevaratnam K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1870</gtr:issn><gtr:outcomeId>58c13977139be6.55807718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65D5EE8F-3ECA-4BB8-A2E3-95B374D7180B</gtr:id><gtr:title>Epac-induced ryanodine receptor type 2 activation inhibits sodium currents in atrial and ventricular murine cardiomyocytes.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental pharmacology &amp; physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/536c54e6501c9878b51f8195fca5c162"><gtr:id>536c54e6501c9878b51f8195fca5c162</gtr:id><gtr:otherNames>Valli H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0305-1870</gtr:issn><gtr:outcomeId>5a2fdaf9a73c89.77349875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>260DF953-32D5-4F1E-9EA0-19A1CF6A3A60</gtr:id><gtr:title>Sodium channel haploinsufficiency and structural change in ventricular arrhythmogenesis.</gtr:title><gtr:parentPublicationTitle>Acta physiologica (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb5bbfe414eb00db62454691d5b71093"><gtr:id>bb5bbfe414eb00db62454691d5b71093</gtr:id><gtr:otherNames>Jeevaratnam K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1748-1708</gtr:issn><gtr:outcomeId>585d57a930dd53.26092429</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05C52507-F999-4191-A033-CF180027D4F8</gtr:id><gtr:title>Arrhythmic effects of Epac-mediated ryanodine receptor activation in Langendorff-perfused murine hearts are associated with reduced conduction velocity.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental pharmacology &amp; physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00fdefe91ff283a2134de1284108f187"><gtr:id>00fdefe91ff283a2134de1284108f187</gtr:id><gtr:otherNames>Li M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1870</gtr:issn><gtr:outcomeId>5a2fdb1f2459b8.04134417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB1D172C-A40C-4B53-B1D6-501D7CFBFEA7</gtr:id><gtr:title>Age-dependent atrial arrhythmic phenotype secondary to mitochondrial dysfunction in Pgc-1? deficient murine hearts.</gtr:title><gtr:parentPublicationTitle>Mechanisms of ageing and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/536c54e6501c9878b51f8195fca5c162"><gtr:id>536c54e6501c9878b51f8195fca5c162</gtr:id><gtr:otherNames>Valli H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0047-6374</gtr:issn><gtr:outcomeId>5a2fda77c69228.71669233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DE387D5-A5E6-4659-A6DA-47BFB4D47C61</gtr:id><gtr:title>Multiple targets for flecainide action: implications for cardiac arrhythmogenesis.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/127b2039bf789f68e0bf88a19be230bd"><gtr:id>127b2039bf789f68e0bf88a19be230bd</gtr:id><gtr:otherNames>Salvage SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5a2fdae186fb37.90497892</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE00FF2D-036F-4ECD-8F81-EBE11C661B32</gtr:id><gtr:title>Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.</gtr:title><gtr:parentPublicationTitle>Acta physiologica (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/127b2039bf789f68e0bf88a19be230bd"><gtr:id>127b2039bf789f68e0bf88a19be230bd</gtr:id><gtr:otherNames>Salvage SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1748-1708</gtr:issn><gtr:outcomeId>5a6efd62f165a1.24798465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16F88124-9EB8-4FC2-B1F7-D98A9F5621AB</gtr:id><gtr:title>The RyR2-P2328S mutation downregulates Nav1.5 producing arrhythmic substrate in murine ventricles.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/067e6a830e341df7e25758a6459b4b3d"><gtr:id>067e6a830e341df7e25758a6459b4b3d</gtr:id><gtr:otherNames>Ning F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>56d4273a11bb45.94417289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8699CB37-3DE8-4B9F-BE15-FAC44E469C0A</gtr:id><gtr:title>Age-dependent electrocardiographic changes in Pgc-1? deficient murine hearts.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental pharmacology &amp; physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0305-1870</gtr:issn><gtr:outcomeId>5a2fda77136844.25459866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DA4ECC9-4531-4BF4-B511-5F2D743EEF7E</gtr:id><gtr:title>A new look at sodium channel ? subunits.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4eb362bffeab29003f1fca0916a098e"><gtr:id>b4eb362bffeab29003f1fca0916a098e</gtr:id><gtr:otherNames>Namadurai S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>5675de5abaed9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7276DCE-6280-42B4-944E-561CE64B1A44</gtr:id><gtr:title>Pro-arrhythmic atrial phenotypes in incrementally paced murine Pgc1?hearts: effects of age.</gtr:title><gtr:parentPublicationTitle>Experimental physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/536c54e6501c9878b51f8195fca5c162"><gtr:id>536c54e6501c9878b51f8195fca5c162</gtr:id><gtr:otherNames>Valli H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0958-0670</gtr:issn><gtr:outcomeId>5a2fd8ab7f9e78.73678112</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA0A36FD-0A2B-486D-A153-3994C557FEFF</gtr:id><gtr:title>From channels to systems: Ca-sensitive Kcurrents, alternans and cardiac arrhythmia.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b89cd909004e1ac07fb1ab74d2c10d3"><gtr:id>6b89cd909004e1ac07fb1ab74d2c10d3</gtr:id><gtr:otherNames>Huang CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>5a2fd34e9469c7.40910936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08F30A84-2897-4483-AF13-BAE123BE94F7</gtr:id><gtr:title>Effects of ageing on pro-arrhythmic ventricular phenotypes in incrementally paced murine Pgc-1?hearts.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>5a2fd8489b0aa6.39878350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9624193-E44A-4429-A5B3-A4CDDD5D8F91</gtr:id><gtr:title>The effects of ageing and adrenergic challenge on electrocardiographic phenotypes in a murine model of long QT syndrome type 3.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf4cfa25fa810c064df0880a080cb510"><gtr:id>cf4cfa25fa810c064df0880a080cb510</gtr:id><gtr:otherNames>Chadda KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a35db0ce43660.46315522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C94865A2-47D5-4048-B162-16FDF622A70B</gtr:id><gtr:title>Sodium channel biophysics, late sodium current and genetic arrhythmic syndromes.</gtr:title><gtr:parentPublicationTitle>Pflugers Archiv : European journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf4cfa25fa810c064df0880a080cb510"><gtr:id>cf4cfa25fa810c064df0880a080cb510</gtr:id><gtr:otherNames>Chadda KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-6768</gtr:issn><gtr:outcomeId>5a2fdbd237f5b6.80539891</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M001288/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>